epilepsy seizure
Conditions
Interventions
None listed
Sponsors
Epilepsie Centrum Kempenhaeghe
Eligibility
Age
2 Years to 99 Years
Inclusion criteria
Inclusion criteria: calibration study: • Adults aged 18 years or older • Normal intelligence;Patients with frontal lobe epilepsy: • Patients aged 8 to18 years • Clinical and electroencephalographic evidence of seizures originating from the frontal lobe. When EEG is not informative, we require the recording of more than one seizure with clinical evidence of seizures originating from the frontal lobe (Provini et al (1)). • Non-symptomatic epilepsy;Healthy control group: • Children aged 8 to 18 years • Normal intelligence/following regular schools
Exclusion criteria
Exclusion criteria: Exclusion criteria for the healthy adult group for the calibration study: • Medical history of head trauma or other diseases/ causes that may underlie cognitive impairment (i.e. psychiatric diseases, unable to speak/understand the Dutch language) • Vision less than +4.5D or - 4.5D • Claustrophobia • Metal implants or other contraindication for MRI • Persons who do not want to get informed whenever structural abnormalities are found during imaging;Exclusion criteria for children with FLE: • Multiple seizure foci involving more than one lobe of the brain documented on previous EEG studies • Frontal lobe seizures thought to be a result of spread to the frontal lobes • MRI lesions on previous structural brain MRI- or CT-scans or symptomatic epilepsy (e.g. tumours, vascular abnormalities, congenital dysgenesia) • Full scale IQ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints: These new techniques may reveal structural abnormalities that are related to FLE or cognitive impairment or refractoriness or all. So endpoints are the macro-structural, micro-structural and functional integrity, seizure history, IQ, and response to anti-epileptic drug treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient-related and epilepsy-related factors responsible for cognitive deterioration and refractoriness | — |
Countries
Netherlands
Outcome results
None listed